Race, response to chemotherapy, and outcome within clinical breast cancer subtypes

Breast Cancer Research and Treatment

Volumn 150, Issue 3, 2015, Pages 667-674

  Tichy, J R ^a,b   Deal, A M ^b,c   Anders, C K ^a,b   Reeder Hayes, K ^a,b   Carey, L A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Breast cancer subtype; Obesity; pCR; Race; Recurrence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; BREAST NEOPLASMS; ETHNOLOGY; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84940000825     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3350-2     Document Type: Article

References (36)

1. Jatoi I, Anderson WF, Rao SR, Devesa SS (2005) Breast cancer trends among black and white women in the United States. J Clin Oncol 23:7836–7841
2. Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357–1362
3. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502
4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975–2010
5. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB (2002) Survival of blacks and whites after a cancer diagnosis. JAMA 287:2106–2113
6. Deshpande AD, Jeffe DB, Gnerlich J, Iqbal AZ, Thummalakunta A, Margenthaler JA (2009) Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res 153:105–113
7. von Drygalski A, Tran TB, Messer K et al (2011) Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int J Breast Cancer 2011:523276
8. Sinicrope FA, Dannenberg AJ (2011) Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 29:4–7
9. Lu Y, Ma H, Malone KE et al (2011) Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 29:3358–3365
10. Rauscher GH, Allgood KL, Whitman S, Conant E (2012) Disparities in screening mammography services by race/ethnicity and health insurance. J Womens Health (Larchmt) 21:154–160
11. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW (2003) Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 81:21–31
12. Newman LA, Mason J, Cote D et al (2002) African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer 94:2844–2854
13. Jatoi I, Becher H, Leake CR (2003) Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer 98:894–899
14. Hershman DL, Unger JM, Barlow WE et al (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 27:2157–2162
15. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728
16. Stark A, Kleer CG, Martin I et al (2010) African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 116:4926–4932
17. O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110
18. Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414
19. Chavez-Macgregor M, Litton J, Chen H et al (2010) Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168–4177
20. Dawood S, Broglio K, Kau SW et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226
21. Fleming I (1997) American Joint Committee on Cancer, American Cancer Society, American College of Surgeons: AJCC Cancer Staging Manual: Philadelphia: Lippincott-Raven
22. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469
23. Zong Y, Zhu L, Wu J et al (2014) Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One 9(8):e95629
24. Prat A, Cheang MC, Martin M et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancers. J Clin Oncol 31(2):203–209
25. Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370
26. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128
27. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4):549–555
28. Friese CR, Pini TM, Li Y et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931–939
29. Neugut AI, Subar M, Wilde ET et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29(18):2534–2542
30. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606
31. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537
32. Hershman DL, Tsui J, Wright JD, et al. (2015) Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol pii: JCO.2014.58.3062. [Epub ahead of print] PMID: 25691670
33. Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446
34. Lund MJ, Mosunjac M, Davis KM et al (2012) 21-gene recurrence scores: racial differences in testing, scores, treatment and outcome. Cancer 118(3):788–796
35. Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences of tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415
36. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167